| A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed (NCT05091619) | China National Biotec Group Company Limited | 2021-10-22 |
| Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine Uptake (NCT04678271) | Yale University | 2021-07-01 |
| A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults (NCT04238975) | Green Cross Corporation | 2019-10-14 |
| Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (NCT03942406) | ILiAD Biotechnologies | 2019-06-15 |
| A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine (NCT04036526) | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2019-06-04 |
| Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States (NCT03973905) | GlaxoSmithKline | 2019-02-15 |
| Immunising Mums Against Pertussis 3 (NCT03578120) | St George's, University of London | 2018-04-24 |
| The Safety of Boostrix Following Routine Immunization of Pregnant Women (NCT03463577) | GlaxoSmithKline | 2018-04-13 |
| A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine (NCT03137927) | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 2017-06-13 |
| Bordetella Pertussis Colonisation Challenge Study (NCT03751514) | University of Southampton | 2017-05-22 |
| Observational Study Describing the Immune Profile Induced By Pertussis Vaccines (NCT03147898) | Sanofi | 2017-04-12 |
| Maternal Tdap Immunization in Guatemala (NCT02301702) | Emory University | 2016-07-01 |
| Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine (NCT02813486) | Green Cross Corporation | 2016-06-01 |
| Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects (NCT02587520) | Sanofi Pasteur, a Sanofi Company | 2015-10-22 |
| Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine (NCT02453048) | Institut National de la Santé Et de la Recherche Médicale, France | 2015-09-01 |
| Influence of BCG on TDaP-IPV Vaccination (NCT02771782) | Radboud University Medical Center | 2015-01-01 |
| Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (NCT01983540) | Sanofi Pasteur, a Sanofi Company | 2013-10-01 |
| Vouchers to Promote Tdap Vaccination (NCT01860378) | Children's Hospital of Philadelphia | 2013-07-01 |
| Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents (NCT01629589) | Sanofi Pasteur, a Sanofi Company | 2012-06-01 |
| Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose (NCT01439165) | Sanofi Pasteur, a Sanofi Company | 2011-11-01 |
| Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants (NCT01444781) | Sanofi Pasteur, a Sanofi Company | 2011-09-01 |
| Montelukast for Persistent Cough in Young People and Adults (NCT01279668) | University of Oxford | 2011-05-01 |
| A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants (NCT01177722) | Sanofi Pasteur, a Sanofi Company | 2010-08-01 |
| Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine (NCT01105559) | Sanofi | 2010-04-01 |
| Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal (NCT01545115) | Biomedical Research Center EPLS | 2008-10-01 |
| Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) (NCT00337428) | Merck Sharp & Dohme LLC | 2006-05-01 |
| Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025) (NCT00325130) | Merck Sharp & Dohme LLC | 2006-04-01 |
| Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine (NCT00662870) | Sanofi | 2001-05-01 |
| Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection (NCT00004422) | IWK Health Centre | 1997-08-01 |